Form D · Biotechnology
ARTELO BIOSCIENCES, INC.
Solana Beach, CA · CIK 0001621221
Offering snapshot reported Apr 6, 2026 · SEC filing
- Reported sold
- $11M Offering amount: $11M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 27, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 6, 2026 | Initial | $10,996,903 | No comparison | 2 | SEC filing |
| Mar 27, 2026 | Initial | $237,300 | No comparison | 1 | SEC filing |
| Mar 27, 2026 | Initial | $113,000 | No comparison | 1 | SEC filing |
| Mar 27, 2026 | Initial | $315,000 | No comparison | 1 | SEC filing |
| Feb 6, 2026 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Nov 10, 2025 | Initial | $3,718,121 | No comparison | 14 | SEC filing |
| Aug 13, 2025 | Initial | $9,475,000 | No comparison | 18 | SEC filing |
| Jul 9, 2025 | Initial | $1,425,000 | No comparison | 8 | SEC filing |
| May 20, 2022 | Initial | $96,972 | No comparison | 1 | SEC filing |
| May 18, 2020 | Initial | $55,000 | No comparison | 2 | SEC filing |
| Jun 4, 2019 | Initial | $4,192,990 | No comparison | 40 | SEC filing |
| Jun 4, 2019 | Initial | $857,430 | No comparison | 59 | SEC filing |
| Sep 14, 2018 | Initial | $525,824 | No comparison | 24 | SEC filing |
| Apr 6, 2018 | Initial | $850,786 | No comparison | 27 | SEC filing |
| Jun 5, 2017 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $880K
- Finders' fees
- $0
- Form D file number
- 021-579170
Commission is 8% of gross amount received at closing and upon cash exercise of investor warrants with an expense allowance of up to $85,000 and 5.5-year warrants to acquire 255,073 shares of common stock at an exercise price of $4.3125 per share.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Apr 6, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John W. Beck | Director |
| Douglas Blayney | Director |
| R. Martin Emanuele | Director |
| Georgia Erbez | Director |
| Tamara A. Favorito | Director |
| Gregory D. Gorgas | Director, Executive |
| Steven Kelly | Director |
| Connie Matsui | Director |
| Peter O'brien | Director, Executive |
| Gregory R. Reyes | Director |
| Tamara A. Seymour | Director |
| Mark Spring | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
505 Lomas Santa Fe, Suite 160
Solana Beach, CA, 92075
Solana Beach, CA, 92075